Nevertheless, a phase II trial of talazoparib in recurrent BRCA1/2-mutated ovarian cancer patients, following primary progression on prior PARP inhibitor, has recently been completed (NCT02326844) [55]. The gene discussed is PARP1; the disease is ovarian cancer.